Skip to content
Boost Up Blog – Lifestyle
Author:
Elutia Inc.
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
November 5, 2026
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
October 22, 2026
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
October 1, 2026
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
September 10, 2026
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
September 2, 2026
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
August 18, 2026
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
August 17, 2026
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
August 13, 2026
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
July 31, 2026
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
July 16, 2026
1
2
Next Page
→